WeVote
Log In

Bill

Bill

HB 5714

AN ACT REQUIRING THE PROVISION OF WRITTEN INFORMATION BY PHARMACISTS CONCERNING THE EFFECTS OF MIFEPRISTONE WHEN DISPENSING TO A PATIENT.

2025 Regular Session Introduced by Mark Anderson and 2 co-sponsors

Connecticut pharmacists must provide written mifepristone effects information to patients, requiring new pharmacy procedures around medication abortion dispensing.

REF. TO JOINT COMM. ON Public Health
#drugs #patients #pharmacists #pregnancy
0
WeVote Research Nonpartisan
Bill Summary · HB 5714

Legislative bill overview

HB 5714 would require Connecticut pharmacists to provide written information about mifepristone's effects to patients when dispensing the medication. Mifepristone is a medication used for medication abortion and certain other medical purposes. The bill mandates a specific informational disclosure at the point of pharmacy dispensing.

Why is this important

This bill directly affects how medication abortion access is regulated in Connecticut, a state where abortion remains legal. The requirement could influence patient experience, informed consent practices, and pharmacy operations, while raising questions about information accuracy, pharmacist liability, and consistency with existing informed consent protocols.

Potential points of contention

  • Scope and accuracy of information: Disagreement over what constitutes necessary "effects" information, whether the state should prescribe specific content, and concerns about bias in written materials
  • Pharmacist role and liability: Questions about whether pharmacists should be information gatekeepers beyond standard dispensing duties, and potential liability if information is disputed or incomplete
  • Reproductive rights framework: Fundamental disagreement between supporters (who view it as informed consent) and opponents (who view it as an abortion restriction tactic in a pro-choice state)

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.